Amendments to the Claims:

The following listing of claims will replace all prior versions, and listings, of claims in the application:

- 1. (Canceled)
- 2. (Currently Amended) The process according to elaim 17, wherein said DNA comprises at least one thiophosphate nucleotide.
- - 4. (Canceled)
- 5. (Currently Amended) The process according to elaim 4claim 18, wherein the treating step comprises adding a quencher to the aqueous solution after the fragmenting and attaching steps.
- 6. (Original) The process according to claim 5, wherein the quencher is a pyrophosphate, thiol derivative, chelating agent, phosphate anion or carbonate anion.
- 7. (Currently Amended) The process according to elaim 4claim 18, wherein the treating step physically separates the labeled nucleic acid fragment from unattached labeling agent in the aqueous solution after the fragmenting and attaching steps.

- 8. (Currently Amended) The process according to elaim 7claim 18, wherein the treating step further includes adding an acid to the mixture after the fragmenting and attaching steps.
- 10. (Currently Amended) The process according to elaim 7claim 18, wherein the treating step uses an organic solvent to separate the labeled nucleic acid fragment from the unattached labeling agent.
- 11. (Original) The process according to claim 10, wherein the organic solvent is 1-butanol, 2-butanol, isopentyl alcohol, 1-pentanol or cyclohexanol.
- 12. (Currently Amended) The process according to elaim 7claim 18, wherein the treating step separates the labeled nucleic acid fragment from the unattached labeling agent by using solid phase extraction of the nucleic acid fragments on a solid support.

- 13. (Original) The process according to claim 12, wherein said solid support is beads, gels, ion exchange resin, reverse phase resin, silica matrix or a membrane.
- 14. (Original) The process according to claim 12, wherein the labeled nucleic acid fragment is eluted from the solid support by using a buffer containing betaine.
- 15. (Currently Amended) The process according to claim 7claim 18, wherein the treating step precipitates the labeled nucleic acid fragment at ambient temperature from a solution that contains betaine, dodecyl trimethylammonium bromide (DTAB) and unlabeled nucleic acid.
- 16. (Currently Amended) The process according to claim 7, A process for fragmenting and labeling a synthetic or natural DNA or RNA nucleic acid, comprising the steps of:

 chemically fragmenting said nucleic acid in the presence of at least one multivalent metal cation in an aqueous solution, to produce a plurality of DNA or RNA fragments having freed terminal phosphates for further reaction;

 attaching a labeling agent on a plurality of said fragments at freed terminal phosphates located at the 3' end and/or 5' end of said fragments; and

 treating said aqueous solution to decrease or eliminate unattached labeling agent, wherein the treating step physically separates the labeled nucleic acid fragment from unattached labeling agent in the aqueous solution after the fragmenting and attaching steps, and wherein the treating step dilutes an in vitro nucleic acid amplification mixture.

 17. (Currently Amended) The process according to claim 1A process for
- 17. (Currently Amended) The process according to claim 1A process for fragmenting and labeling at least one synthetic or natural member selected from the group consisting of DNA and chimeric DNA-RNA polymers, comprising the steps of:

chemically fragmenting said member in the presence of at least one
multivalent metal cation in an aqueous solution, to produce a plurality of DNA or RNA
fragments having freed terminal phosphates for further reaction; and
attaching a labeling agent on a plurality of said fragments at freed terminal
phosphates located at the 3' end and/or 5' end of said fragments, wherein the fragmenting and
attaching steps are performed in a single reaction mixture.
18. (Currently Amended) The process according to claim 4A process for
fragmenting and labeling a synthetic or natural DNA or RNA nucleic acid, comprising the
steps of:
chemically fragmenting said nucleic acid in the presence of at least one
multivalent metal cation in an aqueous solution, to produce a plurality of DNA or RNA
fragments having freed terminal phosphates for further reaction;
attaching a labeling agent on a plurality of said fragments at freed terminal
phosphates located at the 3' end and/or 5' end of said fragments; and
treating said aqueous solution to decrease or eliminate unattached labeling
agent, wherein the fragmenting and attaching steps are performed in a single reaction mixture.
19. (Currently Amended) The process according to claim 1claim 17, wherein the
fragmenting and attaching steps are effected in separate steps.

- 20. (Currently Amended) The process according to claim 4claim 18, wherein the fragmenting and attaching steps are effected in separate steps.
- 21. (Currently Amended) The processing according to elaim 4claim 18, wherein the nucleic acid is DNA, RNA, a chimeric DNA-RNA polymer, DNA comprising at least one thiophosphate nucleotide or RNA comprising at least one thiophosphate nucleotide.

- 22. (Currently Amended) The process according to elaim 1claim 18, wherein the attaching step attaches a label to an internal or terminal thiophosphate or to an internal or terminal phosphate of said fragment.
- 23. (Currently Amended) The process according to elaim 1claim 18, wherein the fragmenting step further includes use of a chemical catalyst.
- 24. (Original) The process according to claim 23, wherein the chemical catalyst is a base selected from the group consisting of imidazole, a substituted analogue of imidazole, and a compound that includes an imidazole ring or substituted analogue of an imidazole ring.
- 25. (Previously Presented) The process according to claim 23, wherein the chemical catalyst is selected from the group consisting of N-methylimidazole, 3-(N-morpholino) propane sulfonic acid (MOPS), N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid (HEPES), piperazine-N,N'-bis (2-ethane sulfonic acid) (PIPES), and bioorganic polyamines.
 - 26. (Canceled)
- 27. (Currently Amended) The processing process according to elaim 26claim 17, wherein the nucleic acid is DNA, RNA, a or chimeric DNA-RNA polymer, DNA is DNA comprising at least one thiophosphate nucleotide or RNA comprising at least one thiophosphate nucleotide.
- 28. (Currently Amended) The process according to elaim 26claim 18, wherein the nucleic acid is an RNA or RNA comprising at least one thiophosphate nucleotide, and the multivalent metal cation is Sr²⁺, Ba²⁺, Pb²⁺, Cd²⁺, Fe²⁺, Ni²⁺, Ru³⁺, Ce³⁺, Eu³⁺, Tb³⁺, Tm³⁺, Yb³⁺ or Lu³⁺, and the fragmenting step further includes use of a chemical catalyst.
- 29. (Currently Amended) The process according to elaim 26 claim 18, wherein the nucleic acid is a DNA and the multivalent metal cation is Tb³⁺, and the fragmenting step further includes use of a chemical catalyst.

- 30. (Currently Amended) The process according to claim 26 claim 18, wherein the nucleic acid is RNA or RNA comprising at least one thiophosphate nucleotide, and the multivalent metal cation is Cr³⁺, Ce³⁺, Yb³⁺, Tb³⁺, Eu²⁺ or Pb²⁺.
- 31. (Currently Amended) The process according to claim 26 claim 18, wherein the nucleic acid is DNA or DNA comprising at least one thiophosphate nucleotide, and the multivalent metal cation is Be²⁺, Cr³⁺, Pb²⁺, In³⁺, Tb³⁺, Ce³⁺, Yb³⁺ or Ni²⁺.
- 32. (Currently Amended) The process according to claim 26 claim 18, wherein the multivalent metal cation is Tb³⁺ or Ce³⁺.
- 33. (Original) The process according to claim 17, wherein the mixture contains the labeling agent in a concentration of between 0.1 mM to 4 mM.
- 34. (Original) The process according to claim 33, wherein the mixture contains the labeling agent in a concentration of between 0.1 mM to 1 mM.
- 35. (Original) The process according to claim 33, wherein the labeling agent concentration is between 0.3 mM to 0.55 mM.
- 36. (Original) The process according to claim 17, wherein the labeling agent contains alkyl halide or haloacetamide reactive functions.
- 37. (Currently Amended) The process according to-claim 1 claim 18, wherein the labeling agent is 5-(bromomethyl)fluorescein, 6-(bromomethyl)fluorescein, 6-iodoacetamidofluorescein or 5-iodoacetamidofluorescein.
- 38. (Currently Amended) The process according to elaim 1claim 17, wherein the synthetic or natural member is DNA polymer.
- 39. (Currently Amended) The process according to elaim-26claim 18, wherein the synthetic or natural nucleic acid is DNA.